Diagnostic and analytical testing services provider LGC has announced the launch of a new genomics division.
Diagnostic and analytical testing services provider LGC has announced the launch of a new genomics division. According to the company it has been seeing successful growth in the area of genomics as part of the company’s Life and Food Sciences division since the 2005 acquisition of AGOWA. Through the acquired genomics company, LGC has provided an array of flexible nucleic acid sample extraction services and products, DNA sequencing, next generation sequencing and genomic services to international pharmaceutical and biotechnology companies and private and public research organizations.
“The launch of LGC Genomics as a new operating division is an exciting step for LGC and presents excellent opportunities for growth,” said John McQuillian, managing director of the new division, in a statement. “Under the new brand, LGC Genomics will continue to advance the development and delivery of first-rate genomic services and products, keeping our customers at the forefront of technology and expertise in this increasingly sophisticated field of science.”
As part of the restructuring process, AGOWA genomics products and services will be rebranded LGC Genomics. For more information visit www.lgc.co.uk
This story originally appeared in The Column. Click here to view that issue.
Determining the Effectiveness and Safety of Cinnamon Derivatives for Diabetes Treatment with HPLC
March 27th 2025Cinnamon and its byproducts have been used for many years because of their antidiabetic effect. In a joint study conducted by Gazi University (Ankara, Turkey) and Düzce University (Düzce, Turkey), high performance liquid chromatographic (HPLC) and thin-layer chromatography (TLC) analyses, macroscopic analyses, and enzyme inhibition assays on diabetes-related enzymes were performed on cinnamon samples to determine whether they are safe to use for health purposes.